Biocept Announces One-for-Thirty Reverse Stock Split
May 17 2023 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that as a
result of its 1-for-30 reverse stock split that became effective at
4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin
trading on a split-adjusted basis with the open of the market
today, May 17, 2023. Biocept’s common stock will continue to trade
under the existing trading symbol “BIOC.”
As a result of the reverse stock split, each 30 pre-split shares
of common stock outstanding were automatically combined and
converted into one issued and outstanding share of common stock. No
fractional shares of common stock were issued to any stockholders
in connection with the reverse stock split. Holders of record will
receive a cash payment in lieu of fractional shares.
Stockholders of record will receive information regarding their
share ownership following the reverse stock split from the
Company’s transfer agent, Continental Stock Transfer & Trust.
Continental Stock Transfer & Trust can be reached at (800)
509-5586 or (212) 509-4000 or by email at
cstmail@continentalstock.com.
For additional information regarding the reverse stock split,
please refer to Biocept’s Current Report on Form 8-K, filed with
the Securities and Exchange Commission on May 16, 2023.
About Biocept
Biocept is a molecular diagnostics company with commercialized
assays for patients with carcinomas or melanomas. Our experts have
spent years working to change the way physicians look at
cerebrospinal fluid (CSF) in cancer patients. Biocept has developed
a unique, patented methodology to isolate cancer material that is
shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and
cell-free DNA (cfDNA). As such, Biocept is a leading commercial
provider of testing services designed to enable clinicians to
rapidly detect and monitor cancer biomarkers from a cerebrospinal
fluid sample.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005283/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From May 2024 to Jun 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Jun 2023 to Jun 2024